There are 2185 resources available
715MO - Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study
Presenter: Danbo Wang
Session: Mini oral session 2: Gynaecological cancers
Resources:
Abstract
LBA44 - Pembrolizumab vs ipilimumab in advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study
Presenter: Caroline Robert
Session: Mini oral session: Melanoma and other skin tumours
Resources:
Abstract
505O - Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C–mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase Ib CodeBreaK 101 study
Presenter: Salvatore Siena
Session: Proffered paper session 2: GI tumours, lower
Resources:
Abstract
716MO - Efficacy and safety of sacituzumab tirumotecan (sac-TMT) plus pembrolizumab in patients with recurrent or metastatic cervical cancer
Presenter: Xiaohua Wu
Session: Mini oral session 2: Gynaecological cancers
Resources:
Abstract
LBA45 - Early switch from targeted to immunotherapy in advanced BRAFV600-positive melanoma: Long-term OS and final PFS results of the randomized phase II ImmunoCobiVem trial
Presenter: Dirk Schadendorf
Session: Mini oral session: Melanoma and other skin tumours
Resources:
Abstract
717MO - SHR-A1921 in platinum-resistant ovarian cancer (PROC): data from a first-in-human (FIH) phase I study
Presenter: Dihong Tang
Session: Mini oral session 2: Gynaecological cancers
Resources:
Abstract
LBA67 - Cabozantinib (C) plus atezolizumab (A) versus 2nd novel hormonal therapy (NHT) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final overall survival (OS) results of the phase III, randomized, CONTACT-02 study
Presenter: Neeraj Agarwal
Session: Proffered paper session: GU tumours, prostate
Resources:
Abstract
609O - CLDN18.2 targeted antibody-drug conjugate (ADC), SHR-A1904, in patients (pts) with gastric/gastroesophageal junction cancer (GC/GEJC): A phase I study
Presenter: Rui-Hua Xu
Session: Proffered paper session 2: Developmental therapeutics
Resources:
Abstract
1077MO - Adjuvant nivolumab v placebo in stage IIB/C melanoma: 3-year results from CheckMate 76K
Presenter: Georgina Long
Session: Mini oral session: Melanoma and other skin tumours
Resources:
Abstract
LBA26 - SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab (bev) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)
Presenter: Kimmie Ng
Session: Proffered paper session 2: GI tumours, lower
Resources:
Abstract